Samrat Pharmachem informs about integrated filing

04 Mar 2025 Evaluate

In compliance with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 dated January 2, 2025, Samrat Pharmachem has informed that it enclosed the Integrated Filing (Financial) for the Quarter and nine months ended December 31, 2024. A. Financial Results Enclosed. B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc - Not Applicable. C. Format for disclosing outstanding default on loans and debt securities - Not Applicable. D. Format for disclosure of related party transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) - Not Applicable. E. Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th Quarter) - Not Applicable. The above information is available on the website of the Company: www.samratpharmachem.com.

The above information is a part of company’s filings submitted to BSE.

Samrat Pharmachem Share Price

312.75 -4.75 (-1.50%)
28-Mar-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1735.45
Dr. Reddys Lab 1144.05
Cipla 1441.70
Lupin 2026.50
Zydus Lifesciences 885.70
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...